Efficacy of Bosentan in Digital Ischemic Ulcers

Annals of Vascular Surgery

Volumn 24, Issue 5, 2010, Pages 690.e1-690.e4

  Todoli Parra, José A ^a   Hernández, Manuel Miralles ^a   Arrébola López, Manuel A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BOSENTAN; LIPOPROSTAGLANDIN E1; ENDOTHELIN RECEPTOR ANTAGONIST; SULFONAMIDE; VASODILATOR AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BUERGER DISEASE; CAPILLAROSCOPY; CASE REPORT; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; INTERMITTENT CLAUDICATION; MALE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; ANGIOSCOPY; COMPLICATION; FINGER; ISCHEMIA; MAGNETIC RESONANCE ANGIOGRAPHY; MIDDLE AGED; PLETHYSMOGRAPHY; SKIN ULCER; SMOKING CESSATION; THROMBOANGIITIS OBLITERANS; TREATMENT OUTCOME; VASCULARIZATION;

AGED; ENDOTHELIN RECEPTOR ANTAGONISTS; FINGERS; HUMANS; ISCHEMIA; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MICROSCOPIC ANGIOSCOPY; MIDDLE AGED; PLETHYSMOGRAPHY; SKIN ULCER; SMOKING CESSATION; SULFONAMIDES; THROMBOANGIITIS OBLITERANS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 77953308700     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.avsg.2010.03.011     Document Type: Article

References (16)

1. Olin J.W. Thromboangiitis obliterans (Buerger's disease). N Engl J Med 343 (2000) 864-869
2. Olin J.W., Young J.R., Graor R.A., Ruschhaupt W.F., and Bartholomew J.R. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation 82 Suppl 5 (1990) IV3-IV8
3. Adar R., Papa M.Z., Halpern Z., et al. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med 308 (1983) 1113-1116
4. Eichhorn J., Sima D., Lindschau C., et al. Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci 315 (1998) 17-23
5. Shionoya S. Diagnostic criteria of Buerger's disease. Int J Cardiol 66 Suppl 1 (1998) S243-S245
6. Kobayashi M., Nishikimi N., and Komori K. Current pathological and clinical aspects of Buerger's disease in Japan. Ann Vasc Surg 20 (2006) 148-156
7. Zdrojowy K., Adamiec R., and Czarnacki M. New aspects of prostaglandin E1 therapeutic influence in thrombo-angiitis obliterans. Pol Arch Med Wewn 108 (2002) 1071-1077
8. Olin J.W., and Shih A. Thromboangiitis obliterans (Buerger's disease). Curr Opin Rheumatol 18 (2006) 18-24
9. De Haro J., Florez A., Fernandez J.L., and Acin F. Treatment of Buerger disease (thromboangiitis obliterans) with bosentan: a case report. BMJ Case Reports (2009) doi:10.1136/bcr. 08.2008.0691. Copyright © 2009 by the BMJ Publishing Group Ltd
10. Fiessinger J.N., and Schäfer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study. Lancet 335 (1990) 555-557
11. Isner J.M., Baumgartner I., Rauh G., et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 28 (1998) 964-973 discussion 73-75
12. Hussein E.A., and el Dorri A. Intra-arterial streptokinase as adjuvant therapy for complicated Buerger's disease: early trials. Int Surg 78 (1993) 54-58
13. Makita S., Nakamura M., Murakami H., et al. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger's disease). Circulation 94 (1996) 211-215
14. Kenji N., Yukihito H., Takashi U., et al. Vascular function and endothelial progenitor cells in thromboangiitis obliterans (Buerger's Disease). Circulation 118 (2008) S-635
15. Czarnacki M., Gacka M., and Adamiec R. A role of endothelin 1 in the pathogenesis of thromboangiitis obliterans (initial news). Przegl Lek 61 (2004) 1346-1350
16. Korn J.H., Mayes M., Matucci Cerinic M., et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50 (2004) 3985-3993